Bank of America Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price

Eli Lilly and Company (NYSE:LLY) had its price target increased by research analysts at Bank of America from $1,251.00 to $1,334.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Bank of America‘s price target would indicate a potential upside of 12.67% from the stock’s current price.

LLY has been the subject of a number of other research reports. Truist Financial raised their price objective on Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the company a “buy” rating in a research note on Wednesday. Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. Rothschild & Co Redburn raised their price objective on shares of Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. Wolfe Research reaffirmed an “outperform” rating and issued a $1,350.00 price target on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,263.41.

Eli Lilly and Company Trading Down 2.7%

Shares of LLY stock traded down $32.97 during trading hours on Friday, hitting $1,183.98. 1,168,878 shares of the company were exchanged, compared to its average volume of 3,199,250. The company has a 50 day simple moving average of $1,091.91 and a two-hundred day simple moving average of $1,032.43. The firm has a market cap of $1.11 trillion, a P/E ratio of 42.07, a P/E/G ratio of 1.51 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the firm earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 35.81 EPS for the current year.

Institutional Trading of Eli Lilly and Company

Hedge funds have recently bought and sold shares of the business. Brighton Jones LLC raised its holdings in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares during the period. Revolve Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after acquiring an additional 40 shares during the period. Schnieders Capital Management LLC. grew its position in shares of Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after purchasing an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC bought a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $356,000. Finally, Nebula Research & Development LLC bought a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $749,000. 82.53% of the stock is currently owned by institutional investors.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly said its Phase 2 neuropathic pain trial reached completion, giving investors another readout to watch for in a potentially large new market. Eli Lilly’s New Neuropathic Pain Trial Reaches Phase 2 Completion: What Investors Should Watch
• Positive Sentiment: Several articles highlighted surging demand for Lilly’s GLP-1 drugs, with sales still accelerating and reinforcing the company’s dominant position in obesity and diabetes treatments. Record Numbers of Americans Are on GLP-1 Drugs. That’s Great News for This Stock.
• Positive Sentiment: Wall Street sentiment remains upbeat, with JPMorgan and RBC reportedly raising price targets, while analysts continue to view Lilly as a strong growth story. JPMorgan resets LLY stock target on drug demand
• Positive Sentiment: Reports that top funds were buying Lilly shares suggest institutional investors are still adding exposure to the name. Top Funds Bet Big On 19 Stocks — Including Eye-Popping Sums On These Five
• Neutral Sentiment: Lilly also announced upcoming Alzheimer’s research presentations at AAIC 2026, which adds to its long-term pipeline narrative but is not an immediate commercial catalyst. Lilly to present Alzheimer’s disease diagnostic and therapeutic research at AAIC 2026
• Negative Sentiment: Tampa General Hospital sued Lilly over alleged pulled 340B discounts, creating a legal and reputational risk around pricing and access practices. Tampa General sues Eli Lilly for allegedly pulling 340B discounts

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.